Key management emerges as a delivery risk in automotive software

Tern plc

As vehicle architectures transition toward software-defined platforms, cryptographic key management is becoming an embedded engineering concern rather than a background cybersecurity task. Software capabilities now define product differentiation in the automotive sector, and this shift is placing new demands on how manufacturers secure, update and validate the integrity of vehicle systems over their full lifecycle.

In earlier automotive cycles, security architectures were simpler. Vehicles had a small number of electronic control units, updates were infrequent, and keys or certificates could be handled manually or with limited automation. As manufacturers expanded into more complex platforms, identity provisioning processes evolved separately across engineering, cloud infrastructure and manufacturing lines.

This fragmentation is now surfacing as a structural constraint across large-scale vehicle programmes. Certificates expire unpredictably, sometimes disabling update functions in fleets already in service. Keys injected during manufacturing may not be recognised by cloud services due to misaligned trust models. Firmware from one generation of hardware may not be signed in a way that is compatible with another, even within the same vehicle line.

In the absence of structured key management, engineering teams may need to pause launches or rework production lines to meet compliance.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search